Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Virtual Congress 2020

Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon

Looking to the future: How can emerging therapeutic options influence the management landscape?

Date

14 Sep 2020

Session

Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon

Presenters

Benjamin Besse

Authors

L.V. Sequist1, B. Besse2

Author affiliations

  • 1 Cancer Center, Massachusetts General Hospital, 02114 - Boston/US
  • 2 Dept Of Cancer Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

An overview of NSCLC

Presenter: Marina Garassino

Session: Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon

Resources:

Webcast

Uncommon EGFR mutations in NSCLC

Presenter: Zofia Piotrowska

Session: Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.